Skip to main content

Table 1 Demographics and medications of patients in the study

From: Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus

Parameter RA SLE OA Controls
Total numbers 26 11 13 21
Age (years)     
   Mean 55.1 42.5 71.2 42.6
   Range 25–76 27–78 62–79 25–64
Sex (n)     
   Female 21 10 8 15
   Male 5 1 5 6
Duration of disease (years)     
   Mean 8.1 9.5 3.3 -
   Range 0.1–37 2–25 0.5–10 -
Clinical parameter (mean ± SD)     
   Leukocytes (109/l) 9.5 ± 2.7 4.3 ± 1.1 7.8 ± 2.7 nd
   CRP (mg/dl) 3.1 ± 3.0 1.1 ± 0.9 0.5 ± 0.6 nd
   ESR (mm/h) 37.5 ± 30.5 34.9 ± 16.7 28.5 ± 19.4 nd
Treatment (n)     
   None 6 - - 21
   Corticosteroids and/or NSAID 7 - 8a -
   Anti-TNF-α therapy 13b - - -
   Predisolone - 11c - -
   Cyclophosphamide (i.v.) - 6 - -
  1. CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; i.v., intravenous; nd, not determined; NSAID, non-steroidal anti-inflammatory drugs; OA, osteoarthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.
  2. aTreatment with buprenorphine (1) or tramadol (1); btreatment with TNF-α-specific antibodies infliximab (6) or adalimumab (3) (mostly in combination with methotrexate) or with the soluble TNF-α receptor etanercept (2); ctreatment with predisolone alone (2), in combination with azathioprine (3), or in combination with cyclophosphamide (6).